Evidence map›Paper›PMID 42151743›Full record

ArticleScandinavian journal of immunology2026

Novel Biomarker for Rheumatoid Arthritis: Serum Peptidylarginine Deiminase 4-Potentiating Activity in an Anti-Citrullinated Protein Antibody-Positive At-Risk Population.

Marta Kaminska, Vijay Joshua, Ewa Bielecka, Tomasz Kantyka, Maja Chrobak, Karin Lundberg, Aase Hensvold, Jan Potempa, Piotr Mydel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scandinavian journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta KaminskaBroegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.ORCID https://orcid.org/0000-0002-8299-7603
Vijay JoshuaDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Ewa BieleckaMałopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.
Tomasz KantykaMałopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.
Maja ChrobakDepartment of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
Karin LundbergDepartment of Medicine Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden.
Aase HensvoldCenter for Rheumatology, Academic Specialist Center, Stockholm Health Services, Region Stockholm, Sweden.ORCID https://orcid.org/0000-0002-7669-3777
Jan PotempaDepartment of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
Piotr MydelBroegelmann Research Laboratory, Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.ORCID https://orcid.org/0000-0001-5072-9391

Funding

Broegelmann FoundationEuropean Research Council 772209King Gustaf V FoundationKnut och Alice Wallenbergs StiftelseNarodowe Centrum Nauki 2018/30/M/NZ1/00367Narodowe Centrum Nauki 2019/34/H/NZ1/00674NIH HHS DE 022597Norges Forskningsråd 296129Vetenskapsrådet 2017-00359
6 · The paper itself

Abstract

Enzymes like peptidylarginine deiminase 4 (PAD4) generate citrullinated epitopes that are crucial in triggering and driving the anti-citrullinated protein antibody (ACPA) response in rheumatoid arthritis. Here, we assessed whether serum PAD4-potentiating activity is associated with subsequent arthritis development among ACPA-positive individuals during the pre-clinical phase. The study included 267 ACPA-positive individuals from the Karolinska Risk-RA cohort, among whom 101 (37.8%) developed arthritis within the observational period (range 22-60 months). We measured the ability of serum to potentiate PAD4 activity by quantifying the generation of citrullinated products using high-performance HPLC. Study participants were then classified as PAD4

Indexed as

Anti-Citrullinated Protein AntibodiesArthritis, RheumatoidBiomarkersProtein-Arginine Deiminase Type 4AdultAgedAutoantibodiesFemaleHumansMaleMiddle AgedRisk FactorsAnti-Citrullinated Protein AntibodiesAutoantibodiesBiomarkersPADI4 protein, humanProtein-Arginine Deiminase Type 4ACPAarthritisbiomarkerPAD4

Identifiers

PMID42151743
PMCPMC13183999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.